Search
Rethinking personalized cancer therapy: targeting minimal residual disease in high-risk lymphoma patients – HiRisk-HiGain
Diffuse large B-cell lymphoma is a heterogeneous disease, 30-40% of all patients failing induction therapy, with limited success of next-line regimens. Among several pathological and genetic features, deregulation of the MYC and BCL2 oncogenes is a strong predictor of negative prognosis: indeed, ove
Personalized planning in radiotherapy through integrative modeling of local dose effect and new dosimetric constraints – PerPlanRT
Radiotherapy for prostate cancer (PC) involves irradiation not only of the target volume but also of portions of healthy neighboring Organs at Risk (OaR) such as bladder, rectum or penile bulb. RT-induced morbidity of sexual, urinary, or rectal nature can arise, impacting Quality of life (QoL). Pred
Computational modelling and functional validation platform for personalised colorectal cancer clinical therapy decision support – ONCOLOGICS
Cancer is the second leading cause of death in the EU. More than 150.000 persons within EU-28 die of colorectal cancer (CRC) every year (more than 10% of all cancer-related deaths). For advanced-stage disease, where surgery is not possible, systemic therapy is used. A few decades ago, chemotherapy w
Optimized T cells for personalized immunotherapy for solid cancer – OptiCAN
The overall goal of OptiCAN is to overcome the present limitations of CAR T cell therapies and extend their application towards personalized immunotherapy of solid tumors through advanced genetic engineering of patient-derived T cells. This will pave the way to bring these optimized T cell products
PRecisiOn medicine in CAD patients: artificial intelliGence for integRated gEnomic, functional and anatomical aSSessment of the coronary collateral circulation – PROGRESS
Coronary artery disease (CAD) is a major burden for patients and health care systems worldwide. The most common cause of CAD is atherosclerosis, an inflammatory disease gradually obstructing arteries, with life-threatening effects in the coronary circulation. Often, the circulation adapts through co
Toward PrecisiOn Medicine for the Prediction of Treatment response in major depressive disorder through stratification of combined clinical and -omics signatures – PROMPT
Major depressive disorder (MDD) is the most common psychiatric disease worldwide, with a huge socio-economic impact. Pharmacotherapy represents the first-line treatment choice; however, only about one third of patients respond to the first trial and about 30% are classified as treatment-resistant (T
Precision drugs Against Resistance In Subpopulations – PARIS
In high-grade serous ovarian cancer (HGSOC) there is an urgent medical need for effective treatment options for the patients with a limited response to both standard chemotherapy and emerging PARP inhibitors. Apart from the mutations in DNA repair pathways, targetable point mutations in tumour suppr
Personalised diagnosis and treatment for refractory focal paediatric and adult epilepsy – PerEpi
Epilepsy is among the most common neurological diseases, affecting between 0.5% and 1% of the general population. Therefore, new diagnosis and treatment methods have a high impact on society. Epilepsy is also among the most frequently diagnosed neurological paediatric disorders, with long-term impli
Validating DIGItal biomarkers for better personalized treatment of Parkinson’s Disease – DIGIPD
Digital biomarkers (DMs) from sensors and devices have the potential to change fundamentally our understanding of Parkinson’s Disease (PD), because they allow for a quantitative and continuous monitoring of disease symptoms, also outside clinics (telemedicine). This includes the possibility to monit
